Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02922894
Recruitment Status : Recruiting
First Posted : October 4, 2016
Last Update Posted : May 30, 2019
Sponsor:
Collaborator:
United States Department of Defense
Information provided by (Responsible Party):
John D. Dingell VA Medical Center

Brief Summary:
This study will investigate potential therapeutic approaches for sleep-disordered breathing (SDB) in patients with chronic cervical spine injury (>6 months post-injury).

Condition or disease Intervention/treatment Phase
Sleep Apnea Spinal Cord Injury Procedure: Acute episodic hypoxia Procedure: Supplemental oxygen Drug: Trazodone Drug: Placebo Procedure: Sham Phase 4

Detailed Description:

Patients with cervical spinal cord injury demonstrate central sleep disordered breathing manifesting as central sleep apnea or a periodic breathing pattern. Understanding the causes of central sleep apnea may be critically important to understanding upper airway obstruction in susceptible individuals, given the critical role of ventilatory motor output in maintaining upper airway patency as evidenced by upper airway narrowing or occlusion at the nadir of ventilator drive during periodic breathing. This study is likely to identify therapeutic strategies that could be tested in large clinical trials, with the ultimate goal of improving quality of life among patients with cervical SCI who also experience central sleep disordered breathing.

To this end the research proposal is aimed as follows:

Specific Aim 1: Test the hypothesis that patients with cervical SCI will demonstrate greater magnitude of long-term facilitation (LTF) following episodic hypoxia during sleep, compared to patients with thoracic Spinal cord injury. This aim will be accomplished by measuring the effect of acute episodic hypoxic ventilation and upper airway mechanics in both groups.

Specific Aim 2: Test the hypothesis that dampening peripheral chemoreceptor activity in patients with cervical SCI and central sleep disordered breathing (SDB) with supplemental oxygen will reduce central respiratory events and decrease respiratory variability during sleep. The aim will be accomplished by providing supplemental oxygen to participants with cervical SCI and central SDB.

Specific Aim 3: Test the hypothesis that administration of trazodone, in patients with cervical spinal cord injury and central SDB will decrease respiratory related arousals and central apnea index, and the propensity to develop central apnea, compared to placebo. To accomplish this aim, the investigators will test the acute effect of trazodone on respiratory related arousals and central sleep apnea, and the chronic effect on central apnea indices and the CO2 reserve.

The investigators will study subjects with SCI at T6 or above who are not on artificial ventilation. To characterize the sleep and breathing state of each subject, polysomnography and upper airway collapsibility will be measured at baseline. Then the following experiments will be conducted: an episodic hypoxia protocol vs normoxia will be used to determine whether cervical SCI will demonstrate greater magnitude of LTF. Experiments will be conducted to see whether dampening peripheral chemoreceptor activity in cervical SCI by giving supplemental oxygen will reduce the central respiratory events and reduce the breathing variability during sleep. A cross over experiment will be done to see whether administration of trazodone in patients with cervical SCI and central SDB decreases respiratory-related arousals and central apnea. The participant will be given the drug/placebo for one week then cross over after a 1 week wash out period to placebo.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Participant)
Primary Purpose: Other
Official Title: Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury
Actual Study Start Date : June 9, 2017
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : February 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Trazodone

Arm Intervention/treatment
Experimental: Acute episodic hypoxia
To test development of ventilatory augmentation following episodic hypoxia, defined as increased Hypoxic Ventilatory Response (HVR) from early to late hypoxic exposure episodes.
Procedure: Acute episodic hypoxia
The subjects will undergo 30 minutes of baseline monitoring followed by 15 episodes of one minute of episodic hypoxia with supplemental CO2 to maintain isocapnia. This is followed by a 45 minute recovery period.

Procedure: Sham
Room air will be administered instead of episodic hypoxia or supplemental oxygen..

Experimental: Supplemental oxygen
To use supplemental oxygen to decrease peripheral chemoreceptor activity in patients with SCI and central SDB. In addition, perform a repeat evaluation after treatment with supplemental oxygen or sham O2 for 6 weeks to determine if correction of chronic intermittent hypoxia, which mitigates sensory LTF, results in decreased propensity to central apnea.
Procedure: Supplemental oxygen
Supplemental oxygen therapy for 6 weeks

Procedure: Sham
Room air will be administered instead of episodic hypoxia or supplemental oxygen..

Experimental: Trazodone or placebo
examine the effect of trazodone on breathing during sleep
Drug: Trazodone
100mg before bedtime

Drug: Placebo
One placebo pill before-bedtime




Primary Outcome Measures :
  1. Change in Tidal Volume [ Time Frame: 1 Week ]
    Change in tidal volume from baseline to recovery period.

  2. Change in CO2 reserve (Delta-PETCO2-AT) [ Time Frame: 1 Week ]
    CO2 reserve (Delta-PETCO2-AT) will be measured after the one week treatment with trazodone and placebo and will be compared to baseline.

  3. Change in Apnea Hypopnea Index (AHI) [ Time Frame: 1 week ]
    AHI will be measured after the one week treatment with trazodone and placebo and compared to baseline.

  4. Change in hypocapnic apneic threshold [ Time Frame: 1 week ]
    Hypocapnic apneic threshold with will be measured after the one week treatment with trazodone and placebo and compared to baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. healthy adults between the ages of 18 - 89
  2. chronic spinal cord injury patients (T6 and above), > 3 months since injury and not on mechanical ventilation, and have not received mechanical ventilation via tracheostomy in the past.

Exclusion Criteria:

  1. subjects ≤ 17 yrs old
  2. Pregnant and lactating females
  3. History of head trauma that resulted in neurological symptoms or loss of consciousness
  4. advanced heart, lung, metabolic, liver or chronic kidney disease.
  5. severe obstructive or restrictive respiratory defect by PFTs or history of tracheostomy
  6. extreme obesity defined for this protocol as BMI ≥ 40 kg/m2 (to avoid the effect of morbid obesity on ventilation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02922894


Contacts
Layout table for location contacts
Contact: M Safwan Badr, M.D. 313-576-3548 m.badr@va.gov

Locations
Layout table for location information
United States, Michigan
John D. Dingell VA Medical Center Recruiting
Detroit, Michigan, United States, 48201
Contact: M. Safwan Badr, MD    313-576-3548      
Sponsors and Collaborators
John D. Dingell VA Medical Center
United States Department of Defense
Investigators
Layout table for investigator information
Principal Investigator: M Safwan Badr, M.D. John D. Dingell VA Medical Center

Layout table for additonal information
Responsible Party: John D. Dingell VA Medical Center
ClinicalTrials.gov Identifier: NCT02922894     History of Changes
Other Study ID Numbers: 1607015110
First Posted: October 4, 2016    Key Record Dates
Last Update Posted: May 30, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Apnea
Sleep Apnea Syndromes
Spinal Cord Injuries
Wounds and Injuries
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Spinal Cord Diseases
Central Nervous System Diseases
Trauma, Nervous System
Trazodone
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Antidepressive Agents, Second-Generation
Antidepressive Agents